Business Context and Reporting Period
This Form 8-K filing by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) reports on events occurring on December 4, 2012. The filing details the completion of a public offering of common stock and warrants.
Key Financial Metrics
- Gross Proceeds: $6,600,000 received from the offering prior to deducting underwriting discounts, commissions, and offering expenses.
- Shares Sold: 19,130,435 firm shares plus 869,565 over-allotment shares, totaling 20,000,000 shares of Common Stock.
- Warrants Issued: Warrants to purchase up to 11,000,000 shares of Common Stock (10,521,739 firm warrants plus 478,261 over-allotment warrants).
- Offering Price: $0.33 per Unit (one share of Common Stock plus a warrant to purchase 0.55 shares).
- Warrant Exercise Price: $0.472 per whole share.
Material Changes
The primary material change is the partial exercise of the underwriters' 45-day over-allotment option. On December 4, 2012, the underwriters (Maxim Group LLC and Burrill LLC) elected to purchase an additional 869,565 shares and corresponding warrants, finalizing the total capital raised in this transaction.
Outlook and Risks
The filing confirms the offering was completed on December 4, 2012. No specific forward-looking guidance, management commentary on future operations, or new risk factors are disclosed in this specific text beyond the standard disclosure of the capital raise. The filing references an opinion of counsel (Patton Boggs LLP) regarding the legality of the securities.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and offering expenses, as only gross proceeds ($6.6 million) are stated.
- Confirm the dilution impact of 20,000,000 new shares and 11,000,000 potential warrant exercises on existing shareholders.
- Review the full Prospectus Supplement (dated November 29, 2012) for detailed use of proceeds and risk factors.
- Note the discrepancy between the request metadata (Opus Genetics) and the filing content (Rexahn Pharmaceuticals).